Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vivtex Corporation focuses its patent efforts in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This prosecution is being handled by 1 distinct examiner and is located within 1 distinct art unit, indicating a concentrated effort on a specific pharmaceutical technology.
ZARA, JANE J is the busiest examiner for the portfolio, managing the 1 pending office action. Since there is only 1 pending office action for the entire company, this examiner is the primary authority for the company's current patent applications. The outcome of this single prosecution will be a significant indicator for the company's intellectual property status in this sector.
The involvement of 1 distinct art unit allows for a streamlined prosecution strategy. Practitioners can focus on the specific rules and trends of that unit without the need to manage multiple examiners. With 1 distinct examiner and 1 pending office action, the company's current interaction with the patent office is highly focused and direct.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014707 | MUCOPENETRATING FORMULATIONS | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014707 | MUCOPENETRATING FORMULATIONS | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18014707 | MUCOPENETRATING FORMULATIONS | ZARA, JANE J | 1637 | §103§112 | Final Rejection | — | Pending | Jan 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVivtex Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jane J Zara has the most, with 1 of Vivtex Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
